Portopulmonary hypertension and hepatopulmonary syndrome, and liver transplantation

International Anesthesiology Clinics

Volumn 44, Issue 3, 2006, Pages 69-82

  Ramsay, Michael A ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; ILOPROST; LIVER ENZYME; NITROUS OXIDE; PROSTACYCLIN; SILDENAFIL;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ANESTHESIA INDUCTION; CLINICAL FEATURE; COIL EMBOLIZATION; DIARRHEA; DRUG INDUCED HEADACHE; ECHOCARDIOGRAPHY; ENZYME BLOOD LEVEL; FLUSHING; HEART FUNCTION; HEART RIGHT VENTRICLE FUNCTION; HEPATOPULMONARY SYNDROME; HUMAN; JAW DISEASE; LEG PAIN; LIVER TRANSPLANTATION; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; LUNG PRESSURE; MORBIDITY; MORTALITY; NAUSEA; PERIOPERATIVE PERIOD; PORTAL HYPERTENSION; PREOPERATIVE CARE; PREVALENCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SURGICAL TECHNIQUE; SYSTEMATIC REVIEW; THORAX RADIOGRAPHY; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; VOMITING; PATHOPHYSIOLOGY;

HEPATOPULMONARY SYNDROME; HUMANS; HYPERTENSION, PORTAL; HYPERTENSION, PULMONARY; LIVER TRANSPLANTATION;

EID: 33747487795     PISSN: 00205907     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aia.0000210800.60630.ac     Document Type: Review

References (54)

1. Kowalski HJ, Abelmann WH. The cardiac output at rest in Laennec's cirrhosis. J Clin Invest. 1953;32:1025-1033.
2. Liu H, Song D, Lee SS. Cirrhotic cardiomyopathy. Gastroenterol Clin Biol. 2002;26:842-847.
3. Hoeper MM, Krowka MJ, Strassburg CP. Portopulmonary hypertension and the hepatopulmonary syndrome. Lancet. 2004;363:1461-1468.
4. Castro M, Krowka M, Schroeder D, et al. Frequency and clinical implications of increased pulmonary artery pressures in liver transplantation. Mayo Clin Proc. 1996;71:543-551.
5. Kuo PC, Schroeder RA, Vagelos RH, et al. Volume-mediated pulmonary responses in liver transplant candidates. Clin Transplant. 1996;10:521-527.
6. Mandell MS. Critical care issues: portopulmonary hypertension. Liver Transplant. 2000;6:S36-S43.
7. Krowka MJ. Editorial: pulmonary hypertension, (high) risk of orthotopic liver transplantation, and some lessons from "primary" pulmonary hypertension. Liver Transplant. 2002;8:389-390.
8. Colle IO, Moreau R, Godinho E, et al. Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study. Hepatology. 2003;37:401-409.
9. Krowka MJ, Plevak DJ, Findlay JY, et al. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transplant. 2000;6:443-450.
10. Ramsay MA, Simpson BR, Nguyen AT, et al. Severe pulmonary hypertension in liver transplant candidates. Liver Transplant Surg. 1997;3:494-500.
11. Kawut SM, Taichman DB, Ahya VN, et al. Hemodynamics and survival of patients with portopulmonary hypertension. Liver Transplant. 2005;11:1107-1111.
12. Robalino BD, Moodie DS. Association between primary pulmonary hypertension and portal hypertension: analysis of its pathophysiology and clinical, laboratory and hemodynamic manifestations. J Am Coll Cardiol. 1991;17:493-498.
13. Schott R, Chaouat A, Launoy A, et al. Improvement of pulmonary hypertension after liver transplantation. Chest. 1999;115:1748-1749.
14. Koneru B, Ahmed S, Weisse AB, et al. Resolution of pulmonary hypertension of cirrhosis after liver transplantation. Transplantation. 1994;58:1133-1135.
15. Rafanan AL, Maurer J, Mehta AC, et al. Progressive portopulmonary hypertension after liver transplantation treated with epoprostenol. Chest. 2000;118:1497-1500.
16. Ramsay MA. Perioperative mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transplant. 2000;6:451-452.
17. Molmenti EP, Ramsay M, Ramsay K, et al. Epoprostenol and nitric oxide therapy for severe pulmonary hypertension in liver transplantation. Transplant Proc. 2001;33:1332.
18. Krowka MJ, Edwards WD. A spectrum of pulmonary vascular pathology in portopulmonary hypertension. Liver Transplant. 2000;6:2421-2422.
19. Ruttner JR, Bartschi JP, Niedermann R, et al. Plexogenic arteriopathy and liver cirrhosis. Thorax. 1980;35:133-136.
20. Sankey EA, Crow J, Mallot SV, et al. Pulmonary platelet aggregation possible cause of sudden perioperative death in adults undergoing liver transplantation. J Clin Pathol. 1993;46:222-227.
21. Lane KB, Machado RD, Pauciulo MW. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, causes familial primary pulmonary hypertension. Nat Genet. 2000;26:81-84.
22. Moller S, Hendriksen JH. Circulatory abnormalities in cirrhosis with focus on neurohumoral aspects. Semin Nephrol. 1997;17:505-519.
23. Cahill PA, Redmond EM, Sitzmann JV. Endothelial dysfunction in cirrhosis and portal hypertension. Pharmacol Ther. 2001;89:273-293.
24. Lee FY, Lu RH, Tsai YT, et al. Plasma interleukin-6 levels in patients with cirrhosis. Relationship to endotoxemia, tumor necrosis factor-alpha, and hyperdynamic circulation. Scan J Gastroenterol. 1996;31:500-505.
25. Tilg H, Wilmer A, Vogel W. Serum levels of cytokines in chronic liver diseases. Gastroenterology. 1992;103:264-274.
26. Thomson JR, Machado RD, Pauciulo MW, et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-11, a receptor member of the TGF-β family. J Med Genet. 2000;37:741-745.
27. Kaspar MD, Ramsay MAE, Shuey CB, et al. Severe pulmonary hypertension and amelioration of severe hepatopulmonary syndrome after liver transplantation. Liver Transplant Surg. 1998;90:177-179.
28. Kuo PC, Plotkin JS, Gaine S, et al. Portopulmonary hypertension and the liver transplant candidate. Transplantation. 1999;67:1087-1093.
29. Kuo PC, Plotkin JS, Johnson LB, et al.. Distinctive clinical features of portopulmonary hypertension. Chest. 1997;112:980-986.
30. Kim WR, Krowka MJ, Plevak DJ, et al. Accuracy of Doppler echocardiography in the assessment of pulmonary hypertension in liver transplant candidates. Liver Transplant. 2000;6:453-458.
31. Colle IO, Moreau R, Godinho E, et al. Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study. Hepatology. 2003;37:401-409.
32. Dennis CM, McNeil KD, Dunning J, et al. Heart-lung-liver transplantation. J Heart Lung Transplant. 1996;15:536-538.
33. Schroeder RA, Rafii AA, Plotkin JS, et al. Use of aerosolized inhaled epoprostenol in the treatment of portopulmonary hypertension. Transplantation. 2000;70:548-550.
34. Krowka MJ, Frantz RP, McGoon MD, et al. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology. 1999;30:641-648.
35. Tan HP, Markowitz JS, Montgomery RA, et al. Liver transplantation in patients with severe portopulmonary hypertension treated with preoperative chronic intravenous epoprostenol. Liver Transplant. 2001;7:745-749.
36. Mair P, Kaehler CH, Pomaroli A, et al. Orthotopic liver transplantation in a patient with severe portopulmonary hypertension. Acta Anaesthesiol Scand. 2001;45:513-518.
37. Ramsay MAE. Liver transplant considerations and outcomes for the portopulmonary hypertension patient. Adv Pulmon Hypertens. 2004;3:9-18.
38. Kuo PC, Johnson LB, Plotkin JS, et al. Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension. Transplantation. 1997;63:604-606.
39. Chua R, Keogh A, Miyashita M. Novel use of sildenafil in the treatment of portopulmonary hypertension. J Heart Lung Transplant. 2005;24:498-500.
40. Hoeper MM, Schwarze M, Ehlerding S, et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med. 2000;342:1866-1870.
41. Rubin LJ, Roux S. Bosantan: a dual endothelin receptor antagonist. Expert Opin Investig Drugs. 2002;11:991-1002.
42. Ramsay MAE, Spikes C, East CA, et al. The perioperative management of portopulmonary hypertension with nitric oxide and epoprostenol. Anesthesiology. 1999;90:299-301.
43. Krowka MJ. Hepatopulmonary syndrome and liver transplantation. Liver Transplant. 2000;6:113-115.
44. Rodriguez-Roisin R, Krowka MJ, Herve MB, et al. Highlights of the ERS task force on pulmonary hepatic vascular disorders (PHD). J Hepatol. 2005;42:924-927.
45. Martinez GP, Barbera JA, Visa J, et al. Hepatopulmonary syndrome in candidates for liver transplantation. J Hepatol. 2001;34:651-657.
46. Krowka MJ. Hepatopulmonary syndrome and portopulmonary hypertension. Curr Treat Options Cardiovasc Med. 2002;4:267-273.
47. Schenk P, Fuhrmann V, Madl C, et al. Hepatopulmonary syndrome: prevalence and predictive value of various cut-offs for arterial oxygenation and their clinical consequences. Gut. 2002;51:853-859.
48. Vallance P, Moncada S. Hyperdynamic circulation in cirrhosis: a role for nitric oxide? Lancet. 1991;337:776-778.
49. Rolla G, Brussino L, Colagrande P, et al. Exhaled nitric oxide and oxygenation abnormalities in hepatic cirrhosis. Hepatology. 1997;26:842-847.
50. Krowka MJ, Dickson ER, Cortese DA. Hepatopulmonary syndrome: clinical observations and lack of therapeutic response to somatostatin analogue. Chest. 1993;104:515-521.
51. Collisson EA, Nourmand H, Fraiman MH, et al. Retrospective analysis of the results of liver transplantation for adults with severe hepatopulmonary syndrome. Liver Transplant. 2002;8:925-931.
52. Arguedas MR, Abrams GA, Krowka MJ, et al. Prospective evaluation of outcomes and predictors of mortality in patients with hepatopulmonary syndrome undergoing liver transplantation. Hepatology. 2003;37:192-197.
53. Taille C, Cadranel J, Bellocq A, et al. Liver Transplantation for hepatopulmonary syndrome: a ten year experience in Paris, France. Liver Transplant. 2003;75:1482-1489.
54. Abrams GA, Rose K, Fallon MB, et al. Hepatopulmonary syndrome and venous emboli causing intracerebral hemorrhages after liver transplantation: a case report. Transplantation. 1999;68:1809-1811.